Suven Life Sciences Ltd
SUVENSuven Life Sciences Ltd
SUVENPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-19.38 | 10.48 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.11 | 6.51 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 518.81 | 564.62 | 648.53 | 312.92 | 28.45 | 21.23 | 17.16 | 27.99 | 40.28 | 26.81 | ||||||||||
Raw Materials | 178.45 | 154.81 | 176.16 | 79.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.63 | ||||||||||
Power & Fuel Cost | 29.32 | 31.50 | 33.56 | 19.37 | 1.63 | 0.00 | 0.00 | 0.00 | 0.26 | |||||||||||
Employee Cost | 40.94 | 52.17 | 61.27 | 36.49 | 17.41 | 18.53 | 21.02 | 18.62 | 18.99 | |||||||||||
Selling & Administrative Expenses | 113.67 | 124.44 | 117.18 | 136.02 | 107.88 | 73.85 | 109.14 | 118.13 | 117.48 | |||||||||||
Operating & Other expenses | 35.48 | 51.54 | 38.89 | 28.56 | 3.21 | 1.04 | 3.93 | 2.55 | 2.83 | |||||||||||
EBITDA | 120.95 | 150.16 | 221.47 | 12.86 | -101.68 | -72.19 | -116.93 | -111.31 | -99.28 | -140.82 | ||||||||||
Depreciation/Amortization | 17.50 | 21.41 | 21.31 | 10.79 | 4.17 | 4.35 | 4.39 | 6.54 | 6.50 | 6.06 | ||||||||||
PBIT | 103.45 | 128.75 | 200.16 | 2.07 | -105.85 | -76.54 | -121.32 | -117.85 | -105.78 | -146.88 | ||||||||||
Interest & Other Items | 5.88 | 5.68 | 4.63 | 1.91 | 0.55 | 0.94 | 0.67 | 0.41 | 0.30 | 0.11 | ||||||||||
PBT | 97.57 | 123.07 | 195.53 | 0.16 | -106.40 | -77.48 | -121.99 | -118.26 | -106.08 | -146.99 | ||||||||||
Taxes & Other Items | 25.73 | 35.88 | 71.84 | 24.06 | -12.18 | -5.32 | 0.00 | 0.00 | -1.00 | -1.00 | ||||||||||
Net Income | 71.84 | 87.19 | 123.69 | -23.90 | -94.22 | -72.16 | -121.99 | -118.26 | -105.08 | -145.99 | ||||||||||
EPS | 0.26 | 0.32 | 0.45 | -0.09 | -0.65 | -5.22 | -8.25 | -6.29 | -4.82 | -6.69 | ||||||||||
DPS | 0.09 | 0.05 | 0.07 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.35 | 0.15 | 0.15 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Suven Life Sciences Ltd | -26.93 | 10.48 | — |
Sun Pharmaceutical Industries Ltd | 44.62 | 6.37 | 0.76% |
Cipla Ltd | 30.06 | 4.62 | 0.85% |
Torrent Pharmaceuticals Ltd | 67.92 | 16.41 | 0.84% |
Price Comparison
Compare SUVEN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 3 Mutual Funds holding Suven Life Sciences Ltd
Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Business Cycle Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6437% | Percentage of the fund’s portfolio invested in the stock 1.18% | Change in the portfolio weight of the stock over the last 3 months -0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/43 (-8) |
Quant Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3685% | Percentage of the fund’s portfolio invested in the stock 2.38% | Change in the portfolio weight of the stock over the last 3 months -1.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/27 (-3) |
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 88/102 (-4) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SUVEN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 17, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateFeb 14, 2019
Dividend/Share
₹1.50
Ex DateEx Date
Feb 14, 2019
Cash Dividend
Ex DateEx DateFeb 6, 2018
Dividend/Share
₹1.50
Ex DateEx Date
Feb 6, 2018
Cash Dividend
Ex DateEx DateFeb 8, 2017
Dividend/Share
₹1.00
Ex DateEx Date
Feb 8, 2017
Cash Dividend
Ex DateEx DateMar 14, 2016
Dividend/Share
₹1.00
Ex DateEx Date
Mar 14, 2016
Net Loss of Suven Life Sciences reported to Rs 49.64 crore in the quarter ended September 2024 as against net loss of Rs 12.68 crore during the previous quarter ended September 2023. Sales declined 16.01% to Rs 2.57 crore in the quarter ended September 2024 as against Rs 3.06 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2.573.06 -16 OPM %-2031.52-768.30 - PBDT-48.19-18.41 -162 PBT-49.64-20.14 -146 NP-49.64-12.68 -291 Powered by Capital Market - Live
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live
The headline equity benchmarks traded with deep cuts in the mid-afternoon trade. The decline was driven by a global market sell-off amid concerns about a potential slowdown in U.S. economic growth. The Nifty traded below the 24,050 mark. Media shares extended losses for the third consecutive trading session. At 14:30 IST, the barometer index, the S&P BSE Sensex slumped 2,345.04 points or 2.90% to 78,636.91. The Nifty 50 index tanked 688.90 points or 2.79% to 24,028.80. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index dropped 3.76% and the S&P BSE Small-Cap index tumbled 4.19%. The market breadth was weak. On the BSE, 599 shares rose and 3,449 shares fell. A total of 104 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, soared 43.38% to 20.53. Economy: The seasonally adjusted HSBC India Services Business Activity Index was at 60.3 in July, down only fractionally from 60.5 and above the neutral mark of 50.0 for the thirty-sixth straight month. The latest reading was more than six points higher than its long-run average and highlighted a substantial upturn in business activity. The HSBC India Composite Output Index posted 60.7 in July, down only fractionally from 60.9 in June and above the crucial 50.0 no-change mark for the thirty-sixth month running. Hence, the latest reading signaled a continuation of the strong growth momentum seen recently. As has been the case since February, the manufacturing industry led the upturn. Total new work rose sharply and at a pace that was considerably above its long-run average. Manufacturers experienced the stronger increase in new orders, despite a slowdown in its rate of expansion. Meanwhile, job creation remained solid across the two segments. Worryingly, charged inflation climbed to a near 11-and-a-halfyear high in July amid stronger increases at goods producers and service providers. Input cost inflation also ticked higher in July, but remained below its long-run average. Manufacturing firms reported stronger cost pressures than their services counterparts. India's foreign exchange reserves registered a decline of $3.471 billion, reaching $667.386 billion during the week ended July 26, according to the latest data from the Reserve Bank of India (RBI). Gold reserves fell by $2.297 billion to $57.695 billion during the week. Special drawing rights (SDRs) decreased by $5 million to $18.202 billion. India's reserve position with the International Monetary Fund (IMF) saw a modest increase of $2 million, reaching $4.612 billion in the reporting week. Buzzing Index: The Nifty Media index fell 4.35% to 2,008.95. The index slipped 6.54% in the three consecutive trading sessions. Nazara Technologies (down 6.56%), Dish TV India (down 6.26%), Saregama India (down 5.76%), Network 18 Media & Investments (down 5.57%), TV18 Broadcast (down 5.53%), Hathway Cable & Datacom (down 5.24%), Zee Entertainment Enterprises (down 4.56%), Tips Industries (down 4.28%), PVR Inox (down 4.07%) and Sun TV Network (down 0.64%) edged lower. Numbers to Track: The yield on India's 10-year benchmark federal rallied 1.16% to 6.980 as compared with previous close 6.977. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 83.8425, compared with its close of 83.7250 during the previous trading session. MCX Gold futures for 5 October 2024 settlement shed 0.25% to Rs 70,154. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.73% to 102.45. The United States 10-year bond yield fell 1.11% to 3.745. In the commodities market, Brent crude for October 2024 settlement lost 80 cents or 0.1.04% to $76.01 a barrel. Stocks in Spotlight: Suven Life Sciences was locked in lower circuit of 5% after the company's consolidated net loss stood at Rs 28.04 crore in Q1 FY25 as compared with a net loss of Rs 24.09 crore in Q1 FY24. Net sales slipped 73.42% year on year (YoY) to Rs 1.01 crore in the quarter ended 30 June 2024. Devyani International rose 0.71%. The company has reported a consolidated net profit of Rs 22.4 crore in Q1 FY25 as against a net loss of Rs 1.6 crore in Q1 FY24. Revenue from operations increased by 44% year-over-year to Rs 1,221.9 crore in the June'24 quarter. VRL Logistics slipped 4.01% after the company's net profit decreased 60.41% to Rs 13.44 crore in Q1 FY25 as compared with Rs 33.95 crore posted in Q1 FY24. Revenue from operations grew by 7.86% to Rs 727.21 crore in Q1 FY25 as compared with Rs 674.22 crore recorded in the corresponding quarter previous year. Powered by Capital Market - Live
Suven Life Sciences reports consolidated net loss of Rs 28.04 crore in the June 2024 quarter
Suven Life hits lower circuit as Q1 net loss widens to Rs 28 cr
Net Loss of Suven Life Sciences reported to Rs 28.04 crore in the quarter ended June 2024 as against net loss of Rs 24.09 crore during the previous quarter ended June 2023. Sales declined 73.42% to Rs 1.01 crore in the quarter ended June 2024 as against Rs 3.80 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1.013.80 -73 OPM %-3023.76-737.11 - PBDT-26.55-22.43 -18 PBT-28.04-24.09 -16 NP-28.04-24.09 -16 Powered by Capital Market - Live
Consolidated net sales slipped 73.42% year on year (YoY) to Rs 1.01 crore in the quarter ended 30 June 2024. Total expenses shed 1.43% to Rs 33.05 crore in June 2024 quarter as against Rs 33.53 crore posted in same quarter last year. Employee benefits expense was Rs 4.69 crore (down 11.17% YoY) while finance costs stood at Rs 0.02 crore (down 60% YoY) during the period under review. R&D and Operational expenses rose marginally on YoY basis to Rs 24.92 crore in first quarter of FY25 compared with Rs 24.79 crore recorded in Q1 FY24. Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Powered by Capital Market - Live
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live
Angel One, Reliance Power, Motherson Wiring, Olectra Green — Buy, Sell Or Hold? AskProfit
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -33.64%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.14% to 0.01%